Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Nasopharyngeal Carcinoma 1Leukemia, Myeloid, Acute 1Esophageal Neoplasms 1Differentiated Thyroid Cancer 1Carcinoma, Hepatocellular 1

Interventions

Capecitabine 27pembrolizumab 19Oxaliplatin 19Fluorouracil 17Cisplatin 17Trastuzumab 14Docetaxel 14Leucovorin 11Paclitaxel 8Irinotecan 8S 1 (combination) 7Epirubicin 6Cyclophosphamide 5tegafur-gimeracil-oteracil 4aldesleukin 4Hyperthermic Intraperitoneal Chemotherapy 4titanium silicide 3spartalizumab 3fludarabine phosphate 3fludarabine 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Ramucirumab 3Nivolumab 3Indocyanine Green 3Gemcitabine 3Carboplatin 3Albumin-Bound Paclitaxel 3Ado-Trastuzumab Emtansine 3vistusertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Stomach Neoplasms × donafenib × Clear all
NCT02489214 2023-05-08

Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Terminated
13 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡